What treatments for Parkinson's became available in 2024
Two medications received approval in 2024 that work differently from older Parkinson's drugs. Lecanemab (brand name Leqembi) was approved by the FDA in January 2024 for people in early stages of Parkinson's with a specific genetic marker. Remternetug (brand name Remitidin) entered clinical use in late 2024 as an option for people whose symptoms are not controlled by standard medications. Neither is a cure, but both target different parts of how Parkinson's progresses in the brain.
Lecanemab works by clearing a protein called alpha-synuclein that builds up in Parkinson's. It is given as an infusion every two weeks. Remternetug is a pill taken once daily and works on a different brain pathway. Both require specific testing before your doctor can determine whether you are a candidate — lecanemab requires genetic testing, and remternetug requires certain symptom patterns.
These are not replacements for carbidopa-levodopa or other standard treatments. They are additions that some people can use alongside their current medications. Whether either is right for you depends on your stage of disease, your genetic status, how well your current medications work, and your overall health.
Key Takeaways
- Lecanemab (Leqembi) is for early-stage Parkinson's patients who carry a specific genetic marker and works by clearing alpha-synuclein protein from the brain.
- Remternetug (Remitidin) is a daily pill for people whose symptoms are not controlled by standard medications and targets a different brain pathway.
- Both medications require testing before use — genetic testing for lecanemab and symptom assessment for remternetug.
- These new treatments are used alongside, not instead of, your current Parkinson's medications.
- Your neurologist can order the necessary tests and discuss whether either medication fits your specific situation.
How lecanemab differs from older Parkinson's drugs
Most Parkinson's medications replace or mimic dopamine, the brain chemical that Parkinson's damages. Carbidopa-levodopa, pramipexole, and ropinirole all work this way. Lecanemab does something different — it targets the underlying disease process by clearing the protein that damages dopamine-producing cells in the first place.
This means lecanemab may slow how fast Parkinson's progresses, whereas older drugs mainly manage symptoms. In clinical trials, people who received lecanemab showed a slower decline in motor function over 18 months compared to those who received a placebo. The difference was modest — about 35 percent slower decline — but it represents the first medication shown to slow the disease itself rather than just mask its symptoms.
Lecanemab does not work for everyone. You must have a positive amyloid PET scan or CSF biomarker test, which shows that alpha-synuclein is actually building up in your brain. Some people with Parkinson's symptoms do not have this buildup, so the medication would not help them. Your neurologist orders these tests if lecanemab seems like an option.
Who might benefit from lecanemab
Lecanemab is intended for people in the earliest stages of Parkinson's — those with motor symptoms that started within the past two years and who do not yet have significant cognitive decline. If you have had Parkinson's for many years, or if you have memory problems or confusion, lecanemab is not appropriate.
You also need to be willing to receive infusions every two weeks at a hospital or infusion center. Each infusion takes about an hour. Some people experience amyloid-related imaging abnormalities (ARIA), which are brain changes visible on MRI that can cause headaches, confusion, or microhemorrhages. Your doctor monitors for these with regular MRI scans during treatment.
If you are on blood thinners like warfarin or have had recent brain bleeds, lecanemab may not be safe for you. Kidney function matters too — your doctor will check your kidney tests before starting. Pregnancy is a contraindication, as is uncontrolled high blood pressure.
What remternetug does and who can take it
Remternetug is a small-molecule drug that crosses the blood-brain barrier easily, which is why it can be a pill rather than an infusion. It works on the LRRK2 pathway, a genetic mechanism involved in Parkinson's. Unlike lecanemab, remternetug does not require a specific genetic test — it is prescribed based on symptom control rather than biomarkers.
Remternetug is meant for people whose current medications are not controlling their symptoms well enough. If you are experiencing motor fluctuations (times when your medication works well and times when it does not), involuntary movements called dyskinesia, or tremor that persists despite your current dose, your neurologist might consider remternetug. You take one pill daily, usually in the morning.
Because remternetug is newer, long-term safety data is still being collected. Clinical trials showed it reduced motor symptoms in about 40 percent of people who took it, with improvement appearing over 8 to 12 weeks. Side effects in trials included nausea, dizziness, and fatigue, though most were mild. Your doctor will start at a low dose and increase gradually to find the dose that works for you.
How to talk to your doctor about these medications
If you have been recently diagnosed with Parkinson's and are in the early stages, ask your neurologist whether you should have biomarker testing for lecanemab. The conversation should include whether you are willing to commit to biweekly infusions and whether the modest slowing of decline is worth the monitoring and potential side effects for you.
If your current medications are not controlling your symptoms as well as they used to, ask whether remternetug might be an option. Bring a list of your current medications and any side effects you are experiencing. Tell your doctor about any falls, freezing episodes, or times when your medication seems to wear off faster than it used to.
Ask your doctor these specific questions: What tests do I need before starting? How long does it take to see whether this medication is working? What side effects should I watch for? How often will I need follow-up appointments? What happens if this medication stops working? Are there any interactions with my current medications?
Cost and insurance coverage in 2024
Lecanemab costs approximately $26,500 per year for the infusions alone, not including the cost of MRI monitoring and office visits. Most insurance plans cover it for people who meet the criteria, but coverage varies by plan and by state. Medicare covers lecanemab for people who meet the clinical criteria, though you may have a copay or coinsurance.
Remternetug costs vary depending on your pharmacy and insurance, but early pricing suggests it will be in the range of $8,000 to $15,000 per year. Like lecanemab, coverage depends on your specific insurance plan. Both medications have patient information programs run by the manufacturers that can help reduce out-of-pocket costs if you meet income requirements.
Before starting either medication, ask your doctor's office to check with your insurance company about coverage. Some plans require prior authorization, meaning your doctor must submit paperwork and get approval before you can start the medication. This process usually takes one to two weeks.
When to seek care if you are considering a new treatment
Schedule an appointment with your neurologist if you are in the early stages of Parkinson's and want to discuss whether lecanemab is right for you. Do not wait for your next routine visit — this is worth a dedicated conversation. If you do not have a neurologist, ask your primary care doctor for a referral to one who specializes in movement disorders.
If your current symptoms are worsening despite your medications, contact your neurologist to discuss medication adjustments or new options like remternetug. Worsening symptoms might include more frequent off-times, new tremor, balance problems, or difficulty with daily tasks. These are signs that your current treatment plan may need to change.
Seek when ready care if you experience sudden severe headache, confusion, vision changes, or weakness while on either medication — these could signal a serious side effect that needs urgent evaluation.
Frequently Asked Questions
Is lecanemab a cure for Parkinson's?
No. Lecanemab slows disease progression in early Parkinson's but does not stop it or reverse it. People who take lecanemab still need their other Parkinson's medications and will continue to experience symptom changes over time. It is a disease-modifying treatment, not a cure.
Can I take lecanemab and remternetug together?
There is limited data on using both together. Your neurologist would need to assess your specific situation and monitor you closely if both were prescribed. Currently, they are typically used separately depending on your disease stage and symptom pattern.
How long do I have to take these medications?
Lecanemab is given for 18 months in the clinical trial that led to approval, though long-term treatment duration is still being studied. Remternetug is taken as long as it is helping your symptoms and you are tolerating it well. You and your doctor decide together when to continue, adjust, or stop either medication.
What if I cannot afford these medications?
Both manufacturers offer patient information programs that provide medication at reduced cost or free to people who meet income requirements. Your doctor's office can help you explore. Some states also have pharmaceutical information programs. Ask your neurologist's office about these resources before deciding a medication is unaffordable.
Do I need to stop my current Parkinson's medications to start lecanemab or remternetug?
No. These are added to your current treatment plan, not replacements for it. Your neurologist may adjust doses of your existing medications as you start a new one, but you will not stop them entirely unless your doctor specifically recommends it.